Anbio Biotechnology Cash and Cash Equivalents
Anbio Biotechnology (NNNN) had Cash and Cash Equivalents of $7.77 million as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-04-07
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $7.77M.
- 2024-12-31: Cash and Cash Equivalents, at Carrying Value $11.76M.
- 2023-12-31: Cash and Cash Equivalents, at Carrying Value $9.69M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2025-12-31 | $7.77M 20-F · filed 2026-04-07 |
| 2024-12-31 | $11.76M 20-F · filed 2026-04-07 |
| 2023-12-31 | $9.69M 20-F · filed 2025-04-28 |